Literature DB >> 26161997

Multifocal Papillary Thyroid Cancer Increases the Risk of Central Lymph Node Metastasis.

Ayham Al Afif1, Blair A Williams2, Mathew H Rigby2, Martin J Bullock3, S Mark Taylor2, Jonathan Trites2, Robert D Hart2.   

Abstract

BACKGROUND: Papillary thyroid cancer (PTC) is the most common thyroid malignancy, with a strong predilection for lymph node metastasis, most commonly to the central neck compartment (level VI). Few studies have evaluated lymph node metastasis in multifocal PTC, and the role of level VI dissection in the management of PTC remains controversial. This retrospective analysis evaluated the rate of level VI lymph node positivity in multifocal PTC, as compared with unifocal disease, in order to inform surgical decision making better.
METHODS: Patients with PTC who underwent total or hemi-thyroidectomy plus level VI lymph node dissection at the authors' institution between January 2008 and June 2014 were included (N=227). The number and laterality of PTC foci, lymphovascular invasion (LVI), extrathyroidal extension (ETE), and positive/total number of level VI lymph nodes were recorded. Fisher's exact test was used to determine univariate associations, and multivariate analysis was done by logistical regression.
RESULTS: There was an association between the number of PTC foci and level VI node positivity (p<0.001), with an odds ratio (OR) of 2.355 in patients with three or more tumor foci (p=0.026). The OR for central neck metastasis was 1.088 with each additional focus of PTC (p=0.018). The risk of level VI node positivity in the presence of one or two foci was only 19%, with no appreciable difference between one and two foci. This risk increased in the presence of between three and nine foci (38%), and 10 or more foci (88%). Level VI node positivity was associated with ETE (p<0.001), LVI (p<0.001), and size of the largest focus (p<0.001). There was no association between level VI lymph node positivity and male sex (p=0.089), bilaterality (p=0.276), or age (p=0.076).
CONCLUSIONS: There is a significant association between multifocal PTC and level VI lymph node positivity, increasing proportionally with the number of foci. These findings recognize multifocality as a sign of tumor aggressiveness, as evidenced by a higher propensity for lymph node metastasis.

Entities:  

Mesh:

Year:  2015        PMID: 26161997     DOI: 10.1089/thy.2015.0130

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  36 in total

Review 1.  Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers.

Authors:  Timothy M Ullmann; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey
Journal:  Gland Surg       Date:  2018-10

2.  Total tumor diameter: the neglected value in papillary thyroid microcarcinoma.

Authors:  J-W Feng; H Pan; L Wang; J Ye; Y Jiang; Z Qu
Journal:  J Endocrinol Invest       Date:  2019-11-20       Impact factor: 4.256

3.  Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.

Authors:  Nathalie Chereau; Etienne Dauzier; Gaëlle Godiris-Petit; Séverine Noullet; Isabelle Brocheriou; Laurence Leenhardt; Camille Buffet; Fabrice Menegaux
Journal:  Langenbecks Arch Surg       Date:  2018-02-14       Impact factor: 3.445

4.  Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?

Authors:  Victoria Harries; Laura Y Wang; Marlena McGill; Bin Xu; R Michael Tuttle; Richard J Wong; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Snehal G Patel; Ian Ganly
Journal:  Surgery       Date:  2019-09-09       Impact factor: 3.982

5.  Nomograms based on preoperative multimodal ultrasound of papillary thyroid carcinoma for predicting central lymph node metastasis.

Authors:  Quan Dai; Dongmei Liu; Yi Tao; Chao Ding; Shouqiang Li; Chen Zhao; Zhuo Wang; Yangyang Tao; Jiawei Tian; Xiaoping Leng
Journal:  Eur Radiol       Date:  2022-02-28       Impact factor: 5.315

6.  Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.

Authors:  Jaroslaw Jendrzejewski; Sandya Liyanarachchi; Rebecca Nagy; Leigha Senter; Paul E Wakely; Andrew Thomas; Fadi Nabhan; Huiling He; Wei Li; Krzysztof Sworczak; Matthew D Ringel; Lawrence S Kirschner; Albert de la Chapelle
Journal:  Thyroid       Date:  2016-07-22       Impact factor: 6.568

7.  Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer.

Authors:  Abbas Ali Tam; Didem Özdemir; Neslihan Çuhacı; Hüsniye Başer; Cevdet Aydın; Aylin Kılıç Yazgan; Reyhan Ersoy; Bekir Çakır
Journal:  Endocrine       Date:  2016-04-18       Impact factor: 3.633

8.  Risk factors for high-volume lymph node metastases in cN0 papillary thyroid microcarcinoma.

Authors:  Chunhao Liu; Yuewu Liu; Lei Zhang; Yunwei Dong; Shenbao Hu; Yu Xia; Bo Zhang; Yue Cao; Ziwen Liu; Ge Chen; Zhonghua Shang; Jinbao Yang; Qinghe Sun; Xiaoyi Li
Journal:  Gland Surg       Date:  2019-10

9.  2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the C-TIRADS.

Authors:  JianQiao Zhou; LiXue Yin; Xi Wei; Sheng Zhang; YanYan Song; BaoMing Luo; JianChu Li; LinXue Qian; LiGang Cui; Wen Chen; ChaoYang Wen; YuLan Peng; Qin Chen; Man Lu; Min Chen; Rong Wu; Wei Zhou; EnSheng Xue; YingJia Li; LiChun Yang; ChengRong Mi; RuiFang Zhang; Gang Wu; GuoQing Du; DaoZhong Huang; WeiWei Zhan
Journal:  Endocrine       Date:  2020-08-21       Impact factor: 3.633

10.  Characteristics of Malignant Thyroid Tumors: A Retrospective Study on 320 Patients.

Authors:  Ivan Abičić; Tin Prpić; Vjeran Bogović; Stjepan Grga Milanković; Hrvoje Mihalj; Andrijana Včeva; Željko Zubčić; Anamarija Šestak; Matej Rezo
Journal:  Acta Clin Croat       Date:  2020-06       Impact factor: 0.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.